Spray-Dried CTB Variant Formulation for UC Mucosal Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ulcerative colitis (UC) treatments fail to directly restore the damaged epithelial barrier and facilitate mucosal healing without suppressing immune function, leading to potential surgical intervention and adverse effects.
Innovation Solution
A spray-dried formulation of a cholera toxin B subunit variant and a saccharide excipient is administered to enhance wound healing and mucosal healing in UC, utilizing a cholera toxin B subunit variant and a saccharide excipient in a pharmaceutical composition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional UC treatments (5-ASAs, corticosteroids, biologics) are used to treat ulcerative colitis, then symptom relief and remission are achieved, but the ability to directly restore the damaged epithelial barrier and facilitate mucosal healing is compromised while immune function is suppressed
Solution Approach 1:
The patent extracts and utilizes the specific mechanism of cholera toxin B subunit variant binding to GM1 ganglioside receptors on epithelial cells, isolating this targeted action from the broader immune-modulating effects of conventional UC treatments. This extraction allows direct epithelial barrier restoration without the harmful immune suppression associated with traditional therapies.
Solution Approach 2:
The cholera toxin B subunit variant acts as an intermediary that facilitates mucosal healing by binding to GM1 receptors on epithelial cells and promoting barrier restoration. This intermediary mechanism directly addresses the epithelial damage without requiring immune system involvement, thereby avoiding immune suppression while achieving reliable mucosal healing.
2Duration of action of stationary object
If conventional UC treatments are used to maintain remission, then symptom control is achieved, but patient adherence decreases over time due to tolerance development and requirement for new treatment strategies
Solution Approach 1:
The cholera toxin B subunit variant provides multi-functional benefits by simultaneously addressing epithelial barrier restoration, mucosal healing, and remission maintenance through a single mechanism. This universal action on GM1 receptor-bearing cells eliminates the need for treatment escalation and maintains patient adherence over extended periods.
Solution Approach 2:
The patent employs parameter changes by modifying the cholera toxin B subunit structure (creating variants with enhanced stability and binding characteristics) to achieve sustained remission maintenance. These parameter modifications ensure long-lasting therapeutic effect without developing tolerance, thereby maintaining high patient adherence.
3Reliability
If biologics are used to treat severe UC, then remission induction and maintenance are achieved in some patients, but serious adverse effects including severe infection and increased cancer risk occur
Solution Approach 1:
The patent extracts the beneficial epithelial-targeting mechanism from cholera toxin B subunit and separates it from the harmful immune suppression effects of biologics. By focusing solely on GM1 receptor binding and epithelial barrier restoration, the treatment achieves remission induction without the serious adverse effects of infection and cancer risk associated with immunosuppressive biologics.
Solution Approach 2:
The patent converts the originally harmful cholera toxin into a beneficial therapeutic by retaining only the B subunit's ability to bind GM1 receptors on epithelial cells. This conversion transforms a pathogen into a tool for direct epithelial repair, achieving remission induction without the harmful immune suppression and adverse effects of conventional biologics.
4Reliability
If biologics are administered to UC patients, then some achieve mucosal healing, but fewer than half of patients are able to achieve sustained clinical remission and mucosal healing
Solution Approach 1:
The patent applies local quality by targeting the specific GM1 receptor-bearing epithelial cells directly with the cholera toxin B subunit variant. This localized action on the epithelial barrier ensures high efficacy in achieving mucosal healing and sustained clinical remission, overcoming the limited effectiveness of systemic biologics that affect multiple cell types and pathways.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively restores the epithelial barrier and facilitates mucosal healing, improving patient adherence and reducing the need for surgical intervention while minimizing immune suppression and adverse effects.
Implementation Method 1
A spray-dried formulation of a cholera toxin B subunit variant and a saccharide excipient
Data Source
AI summary
The disclosure provides, in various embodiments, compositions, for example, powders and pharmaceutical compositions, comprising a spray-dried formulation of a cholera toxin B subunit variant and a saccharide excipient. The disclosure also provides, in various embodiments, methods of making said compositions and methods of treating a disease or enhancing wound healing using said compositions. The disclosure further provides, in various embodiments, liquid compositions comprising a cholera toxin B subunit variant and mannitol.